📰 Presentation Title News
Page 10 - Presentation Title News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Presentation Title. Real-time updates on events, politics, business and more.
March 31, 2022
/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for...
March 4, 2022
04.03.2022 - MIAMI, March 04, 2022 (GLOBE NEWSWIRE) - Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that two abstracts were accepted ... Seite 1
March 4, 2022
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
December 12, 2021
- Expanded Phase 2 data set continues to provide compelling rationale for move to registrational clinical program - - Bomedemstat demonstrated durable clinical improvement in patients with ET who... | December 12, 2021
November 4, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
October 19, 2021
Oral Presentation to Highlight AMT-191 for Fabry DiseaseLEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 19, 2021(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for
October 1, 2021
MAINZ, Germany, October 1, 2021(Nasdaq: BNTX, "BioNTech" or "the Company"), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new
August 17, 2021
Investegate announcements from Carrick Therapeutics, Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021
June 9, 2021
Published: Jun 09, 2021 NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16 th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below. Poster Presentation Title : TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Pa...
June 3, 2021
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and...